



STATE OF IOWA

CHESTER J. CULVER, GOVERNOR
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
KEVIN W. CONCANNON, DIRECTOR

Iowa Medicaid Pharmaceutical and Therapeutics (P & T) Committee Meeting March 13, 2008

**Location: Clive Aquatic Center
1801 N.W. 114th Street
Clive, Iowa 50325**

Time: 9:30 a.m. – 4:30 p.m.

Tentative Agenda

1. Welcome & Introductions
 - a) Committee Members and Staff
 - b) Approval of the minutes
2. Update
 - a) Legislation
 - b) Preferred Drug List (PDL)
 - c) Prior Authorization Criteria/Pro-DUR edits
 - d) Review of P & T Committee Policy and Procedure Manual (Revision of By-laws)
 - e) Medicaid Drug Rebate Issues
3. Public Comment (**See attachment 1 for Conflict of Interest Disclosure**)
4. Closed Executive Session
 - a. Economic Review of the Iowa Medicaid Preferred Drug List, Newly Released Drugs, Newly Released Generic Drugs, New Dosage Forms, and Contracts.
 - b. Review and discussion of the confidential public comments

Lunch Break 12:30 a.m.-1:15 p.m.
5. Preferred Drug List (PDL) discussion and deliberation
(See attachment 2 for order of discussion)
6. Final Recommendations by the P & T Committee on the Iowa Medicaid Preferred Drug List
7. Review of Newly Released Drugs by Dr. Thomas Kline
(See attachment 3 for order of discussion)
8. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
9. Review of Newly Released Generics drugs and New Dosage Forms and Strengths by Dr. Tim Clifford
(See attachment 4 for order of discussion)
10. Final Recommendations by the P & T Committee on Newly Released Generic Drugs and New Dosage Forms and Strengths (Open Session)

****Disclaimer: Executive Sessions may be necessary during the deliberation process****

www.IowaMedicaidPDL.com

For more information contact Sandy Pranger at spranger@ghsinc.com or (515) 725-1272
IOWA MEDICAID ENTERPRISE - 100 ARMY POST ROAD - DES MOINES, IA 50315

Attachment 1

Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee

Speaker Conflict of Interest Disclosure

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons speaking or presenting to the Iowa Medicaid P&T Committee are asked to disclose any financial or other affiliation with organizations that may have a direct or indirect interest in the business in front of the Committee. Those persons speaking or presenting at the P&T Committee meetings are asked to disclose potential conflicts on this form. P&T Committee members disclose potential conflicts each year on a separate form.

A financial interest may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, having research or honoraria paid by the organization, or receiving other forms of remuneration from an organization. An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such a financial relationships or affiliation does not necessarily constitute a conflict of interest and will not preclude an individual from participating or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Your responses below will be read out loud before your presentation to the P&T Committee.

Please check the box of the statement that best applies.

Statement of No Conflicts

I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

Disclosures

I have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

I refuse to state my affiliations

Organization (List additional on the back of the form.)	Role/Relationship (List additional on the back of the form.)

(print name)

(signature)

(date)

Attachment 2
Iowa Medicaid Preferred Drug List

Disclaimer: The Iowa P & T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Acthar HP recommend change status on the PDL to non-preferred
2. Betaseron recommend change status on the PDL from draft preferred to preferred
3. Dostinex recommend to remove from the PDL because the manufacturer discontinued production of the drug and recommend cabergoline to change status on the PDL to preferred.
4. Ethmozine recommend to remove from PDL because manufacturer discontinued production of drug
5. Exubera recommend to remove from PDL because manufacturer discontinued production of drug
6. Hepsera recommend to change status on the PDL to preferred due to current American Association for the Study of Liver Diseases (AASLD) guidelines
7. Inderal LA recommend to change status on the PDL to non-preferred
8. Tyzeka recommend change status on the PDL to non-preferred due to current AASLD guidelines
9. Zemiplar recommend change status on the PDL to preferred

Attachment 3
Newly Released Drugs

Disclaimer: The Iowa P & T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Azor – Recommend status on PDL as non-preferred
2. Bystolic- Recommend status on the PDL as non-preferred
3. Calomist – Recommend status on PDL as non-preferred
4. Chantix- Recommend status on the PDL as preferred with conditions
5. Combigan – Recommend status on PDL as non-preferred
6. Isentress- Recommend status on the RDL as recommended

Attachment 4

Newly Released Generic Drugs and New Dosage Forms

Disclaimer: The Iowa P & T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

NEWLY RELEASED GENERIC DRUGS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Balsalazide	Colazal/Preferred	Non-Preferred
Ciclopirox	Penlac/Non-Preferred	Non-Preferred
Famciclovir	Famvir/Non-Preferred	Non-Preferred
Granisetron	Kytril/Non-Preferred	Non-Preferred
Ipratropium/Albuterol Sol.	DuoNeb/Preferred	Non-Preferred
Pantoprazole	Protonix/Preferred with Conditions	Non-Preferred
Propranolol CR	Inderal LA/Non-Preferred	Preferred
Ramipril	Altace/Preferred	Non-Preferred
NEW DOSAGE FORMS		
Drug Name	Name/Status on PDL/RDL	PDL/RDL Recommendation
Extina Foam	Ketoconazole/Preferred	Non-Preferred
Flector Patch	Diclofenac Sodium/Preferred	Non-Preferred
Pulmicort 1mg Respules	Pulmicort/Preferred < 8 years old	Preferred < 8 years old
Sanctura XR	Santura/Preferred	Preferred
Zemplar Capsules	Zemplar/Preferred	Preferred